Vaccine protection against Zika virus from Brazil

Nature

Volumn 536, Issue 7617, 2016, Pages 474-478

  Larocca, Rafael A ^a   Abbink, Peter ^a   Peron, Jean Pierre S ^b   Zanotto, Paolo M De A ^b   Iampietro, M Justin ^a   Badamchi Zadeh, Alexander ^a   Boyd, Michael ^a   Ng'ang'a, David ^a   Kirilova, Marinela ^a   Nityanandam, Ramya ^a   Mercado, Noe B ^a   Li, Zhenfeng ^a   Moseley, Edward T ^a   Bricault, Christine A ^a   Borducchi, Erica N ^a   Giglio, Patricia B ^a   Jetton, David ^a   Neubauer, George ^a   Nkolola, Joseph P ^a   Maxfield, Lori F ^a   De La Barrera, Rafael A ^c   Jarman, Richard G ^c   Eckels, Kenneth H ^c   Michael, Nelson L ^c   Thomas, Stephen J ^c   Barouch, Dan H ^a,d   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA; VIRUS ENVELOPE PROTEIN; ZIKA VIRUS VACCINE; IMMUNOGLOBULIN G; INACTIVATED VACCINE; SUBUNIT VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ABNORMALITY; CHILD HEALTH; DISEASE TREATMENT; DNA; DRUG DEVELOPMENT; EPIDEMIC; GENETIC ENGINEERING; IMMUNIZATION; RODENT; VACCINATION; VIRAL DISEASE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION SENSITIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS LOAD; ZIKA FEVER; ZIKA VIRUS; ANIMAL; ANTIBODY SPECIFICITY; CD4+ T LYMPHOCYTE; CHEMISTRY; COMPLICATION; GENE DELETION; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROCEPHALY; VIROLOGY; ZIKA VIRUS INFECTION;

BRAZIL;

FLAVIVIRUS; MUS; ZIKA VIRUS;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; BRAZIL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE DELETION; HUMANS; IMMUNOGLOBULIN G; MICE; MICROCEPHALY; VACCINES, DNA; VACCINES, INACTIVATED; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 84976361840     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature18952     Document Type: Article

References (30)

1. Fauci, A. S. & Morens, D. M. Zika virus in the Americas - yet another arbovirus threat. N. Engl. J. Med. 374, 601-604 (2016).
2. Petersen, L. R., Jamieson, D. J., Powers, A. M. & Honein, M. A. Zika virus. N. Engl. J. Med. 374, 1552-1563 (2016).
3. Mlakar, J. et al. Zika virus associated with microcephaly. N. Engl. J. Med. 374, 951-958 (2016).
4. Calvet, G. et al. Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study. Lancet Infect. Dis. 16, 653-660 (2016).
5. Brasil, P. et al. Zika virus infection in pregnant women in Rio de Janeiro - preliminary report. N. Engl. J. Med. http://dx.doi.org/10.1056/ NEJMoa1602412 (2016).
6. Driggers, R. W. et al. Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. N. Engl. J. Med. 374, 2142-2151 (2016).
7. Rasmussen, S. A., Jamieson, D. J., Honein, M. A. & Petersen, L. R. Zika virus and birth defects - reviewing the evidence for causality. N. Engl. J. Med. 374, 1981-1987 (2016).
8. Johansson, M. A., Mier-Y-Teran-Romero, L., Reefhuis, J., Gilboa, S. M. & Hills, S. L. Zika and the risk of microcephaly. N. Engl. J. Med. 375, 1-4 (2016).
9. Li, C. et al. Zika virus disrupts neural progenitor development and leads to microcephaly in mice. Cell Stem Cell 19, 120-126 (2016).
10. Miner, J. J. et al. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell 165, 1081-1091 (2016).
11. Cugola, F. R. et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534, 267-271 (2016).
12. Garcez, P. P. et al. Zika virus impairs growth in human neurospheres and brain organoids. Science 352, 816-818 (2016).
13. Qian, X. et al. Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. Cell 165, 1238-1254 (2016).
14. Tang, H. et al. Zika virus infects human cortical neural progenitors and attenuates their growth. Cell Stem Cell 18, 587-590 (2016).
15. Brasil, P. et al. Guillain-Barré syndrome associated with Zika virus infection. Lancet 387, 1482 (2016).
16. Faria, N. R. et al. Zika virus in the Americas: Early epidemiological and genetic findings. Science 352, 345-349 (2016).
17. Thomas, S. J. et al. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am. J. Trop. Med. Hyg. 88, 73-88 (2013).
18. Tartaglia, L. J. et al. Production of mucosally transmissible SHIV challenge stocks from HIV-1 circulating recombinant form 01-AE env sequences. PLoS Pathog. 12, e1005431 (2016).
19. Lazear, H. M. et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe 19, 720-730 (2016).
20. Rossi, S. L. et al. Characterization of a novel murine model to study Zika virus. Am. J. Trop. Med. Hyg. 94, 1362-1369 (2016).
21. Hombach, J., Solomon, T., Kurane, I., Jacobson, J. & Wood, D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23, 5205-5211 (2005).
22. Kreil, T. R., Burger, I., Bachmann, M., Fraiss, S. & Eibl, M. M. Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. Clin. Exp. Immunol. 110, 358-361 (1997).
23. Mason, R. A., Tauraso, N. M., Spertzel, R. O. & Ginn, R. K. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl. Microbiol. 25, 539-544 (1973).
24. Martin, J. E. et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J. Infect. Dis. 196, 1732-1740 (2007).
25. Ledgerwood, J. E. et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J. Infect. Dis. 203, 1396-1404 (2011).
26. Martinez, L. J. et al. Safety and immunogenicity of a dengue virus serotype-1 purified-inactivated vaccine: results of a phase 1 clinical trial. Am. J. Trop. Med. Hyg. 93, 454-460 (2015).
27. Fernandez, S. et al. An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques. Am. J. Trop. Med. Hyg. 92, 698-708 (2015).
28. Demicheli, V., Debalini, M. G. & Rivetti, A. Vaccines for preventing tick-borne encephalitis. Cochrane Database Syst. Rev. CD000977 (2009).
29. Demicheli, V., Graves, P., Pratt, M. & Jefferson, T. Vaccines for preventing tick-borne encephalitis. Cochrane Database Syst. Rev. CD000977 (2000).
30. Erra, E. O. & Kantele, A. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis. Expert Rev. Vaccines 14, 1167-1179 (2015).